

# 1 Protection of Omicron bivalent vaccine, previous infection, and their induced neutralizing antibodies 2 against symptomatic infection with Omicron XBB.1.16 and EG.5.1

3  
4 Shohei Yamamoto<sup>1</sup> Ph.D.; Kouki Matsuda<sup>2</sup> Ph.D.; Kenji Maeda<sup>2,3</sup> M.D., Ph.D.; Tetsuya Mizoue<sup>1</sup> M.D., Ph.D.;  
5 Kumi Horii<sup>4</sup> R.N., Kaori Okudera<sup>5</sup> R.N.; Tomofumi Tan<sup>6</sup> M.T.; Yusuke Oshiro<sup>6</sup> M.T.; Natsumi Inamura<sup>6</sup> M.T.;  
6 Takashi Nemoto<sup>6</sup> M.T.; Junko S. Takeuchi<sup>7</sup> Ph.D.; Maki Konishi<sup>1</sup>; Haruhito Sugiyama<sup>8</sup> M.D., Ph.D.; Nobuyoshi  
7 Aoyanagi<sup>9</sup> M.D., Ph.D.; Wataru Sugiura<sup>10</sup> M.D., Ph.D.; Norio Ohmagari<sup>11</sup> M.D., Ph.D.

8  
9 <sup>1</sup> Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo,  
10 Japan

11 <sup>2</sup> Division of Antiviral Therapy, Joint Research Center for Human Retrovirus Infection, Kagoshima University, Kagoshima, Japan

12 <sup>3</sup> Department of Refractory Viral Infection, Research Institute, National Center for Global Health and Medicine, Tokyo, Japan

13 <sup>4</sup> Infection Control Office, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan

14 <sup>5</sup> Infection Control Office, Kohnodai Hospital of the National Center for the Global Health and Medicine, Chiba, Japan

15 <sup>6</sup> Department of Laboratory Testing, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan

16 <sup>7</sup> Department of Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and  
17 Medicine, Tokyo, Japan

18 <sup>8</sup> Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan

19 <sup>9</sup> Kohnodai Hospital of the National Center for the Global Health and Medicine, Chiba, Japan

20 <sup>10</sup> Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan

21 <sup>11</sup> Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan

22  
23 **Running title:** Protection against XBB.1.16/EG.5 infection

24  
25 **Corresponding Author:** Shohei Yamamoto, Ph.D.

26 Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and  
27 Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan; email: [syamamoto@hosp.ncgm.go.jp](mailto:syamamoto@hosp.ncgm.go.jp)

28  
29 **Alternative Corresponding Author:** Tetsuya Mizoue

30 Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and  
31 Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan; email: [mizoue@hosp.ncgm.go.jp](mailto:mizoue@hosp.ncgm.go.jp)

32  
33 **Word Count:** Abstract, 248; main text, 2971.

## 34 35 **Main points:**

36 In the era when the Omicron XBB vaccine was unavailable, the Omicron BA bivalent vaccine did not confer the  
37 neutralizing activity and protection against Omicron XBB.1.16 and EG.5.1 symptomatic infection. The previous  
38 infection afforded neutralizing titers and protection against symptomatic infection with these variants.

39 **Abstract ≤250**

40 **Background**

41 Data are limited on the protective role of the Omicron BA bivalent vaccine, previous infection, and their induced  
42 neutralizing antibodies against Omicron XBB.1.16 and EG.5.1 infection.

43 **Methods**

44 We conducted a nested case-control analysis among tertiary hospital staff in Tokyo who had received three or  
45 more doses of COVID-19 vaccines and donated blood samples in June 2023 (1 month before Omicron XBB.1.16  
46 and EG.5.1 wave). We identified 206 symptomatic cases between June and September 2023 and selected their  
47 controls with 1:1 propensity-score matching. We examined the association of vaccination, previous infection, and  
48 preinfection live-virus neutralizing antibody titers against Omicron XBB.1.16 and EG.5.1 with the risk of COVID-  
49 19 infection.

50 **Results**

51 Previous infection during Omicron BA- or XBB-dominant phases was associated with a significantly lower infection  
52 risk during the XBB.1.16 and EG.5.1 dominant phase than infection-naïve with 70% and 100% protection,  
53 respectively, whereas Omicron BA bivalent vaccination showed no association. Preinfection-neutralizing titers  
54 against XBB.1.16 and EG.5.1 were 39% (95%CI: 8–60) and 28% (95%CI: 8–44), respectively, lower in cases than  
55 in matched controls. Neutralizing activity against XBB.1.16 and EG.5.1. were somewhat detectable in the sera of  
56 individuals with previous infection but barely detectable in those who were infection-naïve and received the  
57 Omicron bivalent vaccine.

58 **Conclusions**

59 In the era when the Omicron XBB vaccine was unavailable, the Omicron BA bivalent vaccine did not confer the  
60 neutralizing activity and protection against Omicron XBB.1.16 and EG.5.1 symptomatic infection. The previous  
61 infection afforded neutralizing titers and protection against symptomatic infection with these variants.

62 **Keywords:** COVID-19; Omicron; bivalent vaccine; previous infection; neutralizing antibody; protection.

## Introduction

As of 2024, four years after the initial outbreak, the COVID-19 pandemic is still ongoing due to the persistent mutation cycle of the SARS-CoV-2. In late 2020, clinical trials showed that the COVID-19 vaccination was highly effective in lowering the risk of SARS-CoV-2 infection and severe outcomes [1, 2]. In late 2021, COVID-19 cases rapidly increased due to the Omicron BA subvariants among the vaccinated population. In 2022, a subsequent updated Omicron BA bivalent vaccine lowered the risk of Omicron BA infections [3]. In early- to mid-2023, the Omicron XBB subvariants (XBB.1.5, XBB.1.16, and EG.5), with multiple spike protein mutations compared to earlier BA subvariants [4-6], dominated worldwide. Until the Omicron XBB vaccine became available in September 2023, people had to rely on immunity acquired by existing vaccines or prior infections against Omicron XBB subvariants.

In immunological studies, both Omicron bivalent BA vaccines and Omicron BA infection elicited neutralizing activity against XBB.1.5, XBB.1.16, and EG.5 subvariants, albeit to a limited extent [7-9]. In epidemiological studies, while the Omicron BA bivalent vaccine or previous Omicron BA infection were reported to confer moderate protection against the Omicron XBB.1.5 infection [3, 10, 11], the evidence regarding the protection against Omicron XBB.1.16 and EG.5 infection is limited. In a cohort study of 51,017 U.S. healthcare workers, the previous Omicron infection, but not the Omicron bivalent vaccine, was associated with a lower risk of subsequent infection when Omicron XBB.1.16 and EG.5 subvariants were dominant [12]. Quantitative association between vaccine- or infection-acquired neutralizing activity against Omicron XBB.1.16 and EG.5 and the risk of infection with these variants remains elusive.

In June 2023, when a month before the Omicron XBB.1.16 and EG.5.1 epidemic in Japan (July to September 2023), we performed a serological survey among the staff of the National Center for Global Health and Medicine (NCGM), Tokyo, and stored blood samples. This situation prompted us to investigate whether the Omicron bivalent vaccine and previous infection could confer protection against Omicron XBB.1.16 and EG.5.1 infection and its induced neutralizing antibody titers could correlate with infection protection.

Here, we examined the protection of the Omicron bivalent vaccine and previous infection against Omicron XBB.1.16 and EG.5.1 infection and compared the live-virus and preinfection-neutralizing antibody titers between infected cases and controls in the nested case-control study of recipients with three or more doses of COVID-19 historical monovalent or Omicron BA bivalent vaccines.

## Methods

### *Study setting*

A repeat serological study was conducted at the NCGM in Japan in July 2020 to monitor the spread of SARS-CoV-2 infection among staff during the COVID-19 epidemic. The details of this study have been reported elsewhere [13-15]. In summary, we have completed eight serosurveys as of June 2023, where we measured anti-SARS-CoV-2 nucleocapsid- (all serosurveys) and spike-protein antibodies (from the second serosurvey onward) for all the participants using both Abbott and Roche assays, stored serum samples at -80°C, and collected information on COVID-19-related factors (vaccination, occupational infection risk, infection prevention practices, behavioral factors, etc.) via a questionnaire. The self-reported vaccination status was validated using objective information from the NCGM Labor Office. Written informed consent was obtained from all the participants. This study was approved by the NCGM Ethics Committee (approval number: NCGM-G-003598).

### *Case-Control Selection*

We conducted a nested case-control study among the staff who participated in the eighth survey conducted in June 2023 and had received three or more doses of the mRNA COVID-19 vaccine (any of the patterns of historical monovalent vaccine, Omicron BA.1 and wild-type bivalent vaccine, and Omicron BA.4/5 and wild-type bivalent vaccine) manufactured by Pfizer or Moderna (**Figure S1**). Of the 2,569 participants, 2,409 received three or more doses of the mRNA COVID-19 vaccines and donated blood samples. Of those, we excluded 16 participants who lacked information on covariates: body mass index (n=10), alcohol drinking status (n=2), living arrangement status (n=5), adherence to infection prevention practice (n=3), and infection risk behaviors (n=2). We further excluded 19 participants with insufficient volume of serum sample (<100µL), leaving 2374 participants as the base population.

We followed the participants for COVID-19 incidence using the COVID-19 patient records documented by the NCGM Hospital Infection Prevention and Control Unit. As per the NCGM rule, staff should undergo PCR or antigen test for COVID-19 when they have COVID-19-compatible symptoms, and if it tests positive, they must report the results to the NCGM Hospital Infection Prevention and Control Unit. During the follow-up (June to September 2023), we identified 217 COVID-19 patients. We defined cases as symptomatic SARS-CoV-2 infection. Participants infected after additional vaccination during follow-up were considered cases if the infection occurred within 14 days after the vaccination, assuming they were not sufficiently immunized with the additional booster until then. After excluding 11 asymptomatic patients, leaving 206 were included as cases (**Figure S1**). We selected

123 a control for each case using propensity score matching to compare preinfection anti-spike antibody titers. The  
124 details of the case-control matching algorithm are described in **supplemental text 1**. We randomly selected 50  
125 pairs of these matched pairs and measured live virus–neutralizing antibody titers to compare neutralizing  
126 antibodies between the groups.

### 128 *Antibody Testing*

129 We measured neutralizing activity against Wild-type, Omicron XBB.1.16, and Omicron EG.5.1 in the sera of  
130 patients and controls by quantifying the serum-mediated suppression of the cytopathic effect of each SARS-CoV-  
131 2 strain in HeLa<sub>hACE2-TMPRSS2</sub> cells [16, 17]. The details of the measurement methods are described in  
132 **supplemental text 2**.

133 We assessed anti-SARS-CoV-2 antibodies in all the participants at baseline and retrieved data for the case-  
134 control pairs. We quantitatively measured the levels of antibodies against the receptor-binding domain (RBD) of  
135 the SARS-CoV-2 spike protein using the AdviseDx SARS-CoV-2 IgG II assay (Abbott) (i.e., anti-RBD  
136 immunoglobulin [Ig] G) and Elecsys<sup>®</sup> Anti-SARS-CoV-2 S (Roche) (i.e., anti-RBD total). We also qualitatively  
137 measured antibodies against the SARS-CoV-2 nucleocapsid (N) protein using the SARS-CoV-2 IgG assay  
138 (Abbott) and Elecsys<sup>®</sup> Anti-SARS-CoV-2 (Roche).

### 140 *Previous infection status at baseline*

141 Previous infection was defined as a self-reported history of COVID-19 (confirmed against in-house COVID-  
142 19 registry) at baseline or anti-N seropositive with any of the two assays (Roche  $\geq 1.0$  COI or Abbott  $\geq 1.40$  S/C)  
143 at any of the first (July 2020) through eighth (June 2023: baseline) surveys. We defined participants with no history  
144 of COVID-19 but seropositive on N antibodies as undiagnosed infection [18]. We defined phases of previous  
145 infection referring to the timing of the last diagnosis: Pre-Omicron (February 2020 to December 2021), Omicron  
146 BA (January 2022 to March 2023), and Omicron XBB (April 2024 to June 2024).

### 148 *Statistical analysis*

149 We used conditional logistic regression while accounting for the matched design to examine the association  
150 of vaccination status (doses of any COVID-19 vaccines and dose of Omicron BA vaccines) and previous infection  
151 status with COVID-19 infection risk. We used a generalized estimating equation (GEE) with group assignment  
152 (case or control) and a robust variance estimator to compare the interval from the last vaccination or COVID-19

153 diagnosis to baseline blood sampling. To examine the difference in preinfection antibody levels between cases  
154 and controls, we compared the log-transformed titers of neutralizing (Wild-type, Omicron XBB.1.16 and Omicron  
155 EG.5.1) and anti-RBD (IgG and total) antibodies between matched pairs using a GEE model with group  
156 assignment and a robust variance estimator. Then, we back-transformed and presented these values as geometric  
157 mean titers (GMTs) with 95% confidence intervals (CIs). We repeated the GEE analysis by restricting matched  
158 pairs to infection-naïve pairs at baseline (i.e., both case and matched controls had no history of COVID-19 and  
159 were negative on anti-N assays) as sensitivity analysis. We used the Kruskal–Wallis test to compare the  
160 neutralizing titers across vaccination status (historical monovalent vaccine only or the historical monovalent plus  
161 Omicron bivalent vaccines) and previous infection status (infection-naïve or previously infected). To examine the  
162 difference in neutralizing titers across the timing of previous infection, we used a linear regression model while  
163 adjusting age, sex, a history of Omicron bivalent vaccination, and the interval between the last vaccination and  
164 blood sampling. For the analyses of neutralizing antibody titers, values below the limit of detection (LOD)  
165 ( $NT_{50} < 40$ ) were given the LOD value. Statistical analyses were performed using Stata version 18.0 (StataCorp  
166 LLC), and graphics were generated using GraphPad Prism 9 (GraphPad, Inc.). All P-values were 2-sided, and the  
167 statistical significance was set at  $P < 0.05$ .

## 170 Results

### 171 *Distribution of circulating SARS-CoV-2 variants during follow-up*

172 **Figure 1** shows the distribution of SARS-CoV-2 lineages in Japan during the study period (June to  
173 September 2023), analyzed using all domestic genome sequences registered in the GISAID EpiCov database  
174 (<https://gisaid.org>). During the study period, 27,899 samples were extracted for sequences, and the most frequent  
175 subvariants were Omicron XBB variants with a relative frequency of 91%. According to subvariants, the most  
176 frequent subvariants were Omicron XBB.1.16 (23%), following Omicron EG.5 (22%). From June to September  
177 2023, the relative frequency of Omicron XBB.1.16 decreased (28% to 18%), while that of Omicron EG.5 increased  
178 (13% to 31%).

### 180 *Baseline characteristics before and after propensity score matching*

181 We ascertained 206 symptomatic breakthrough infection cases during the follow-up in the before-matching  
182 cohort, with an incidence rate of 12.7 per 10000 person-days. Cases were younger and more likely to be female

183 and nurses than the controls in the before-matching cohort (**Table 1**). After propensity matching with a 1:1 ratio,  
184 the 206 matched pairs were well-balanced regarding all the baseline characteristics.

#### 185 186 *Vaccination and previous infection statuses and risk of COVID-19 infection*

187 The number of existing mRNA vaccinations and those of the Omicron BA bivalent vaccination were not  
188 associated with the risk of COVID-19 infection (**Table 2**). In the analysis of any mRNA vaccines, the OR (95% CI)  
189 of 3 to 6 doses against infection were 1 (reference), 1.01 (0.62 to 1.63), 0.78 (0.47 to 1.30), and 1.04 (0.32 to 3.39),  
190 respectively. For the analysis of Omicron BA bivalent vaccines, the OR (95% CI) of no vaccination (monovalent  
191 vaccine only), 1-dose, and 2-dose were 1 (reference), 0.79 (0.52 to 1.20), 1.40 (0.32 to 6.06), respectively. The  
192 mean interval days between the last vaccination and baseline blood sampling were not statistically different  
193 between cases and controls (287 v.s. 274 days).

194 Previous infection at the Omicron BA or XBB phase, but not at the pre-Omicron phase, was significantly  
195 associated with a lower risk of COVID-19 infection during the follow-up (**Table 2**). Compared to infection-naïve,  
196 the OR (95% CI) of previous infection at pre-Omicron and Omicron BA waves against infection were 0.20 (0.03 to  
197 1.21) and 0.30 (0.18 to 0.50), respectively. No COVID-19 infection occurred in the group of previous infection at  
198 the Omicron XBB wave (i.e., OR=0.00). Undiagnosed infection was also associated with a lower risk of infection  
199 than infection-naïve, with an OR (95% CI) of 0.27 (0.13 to 0.55). Among the participants with a history of COVID-  
200 19, the interval between the last infection and baseline blood sampling was statistically longer in cases than in  
201 controls, with a mean difference (95% CI) of 81 (25 to 137) days.

#### 202 203 *Preinfection antibody titers between the cases and matched controls*

204 The GMT of preinfection-neutralizing antibodies against Wild-type, Omicron XBB.1.16, and EG.5.1 were 377,  
205 68, and 49, and their detection rate (>40 NT<sub>50</sub>) were 89%, 28%, and 14%, respectively, among total samples of  
206 cases and controls (**Figure S2**).

207 Preinfection anti-RBD and neutralizing antibody titers were lower in cases than in controls. The GEE-  
208 predicted GMTs (95% CI) of the anti-RBD IgG antibody on Abbott assay (AU/ml) was 6189 (5365–7141) for cases  
209 and 11959 (10238–13970) for controls with a predicted case-to-control ratio of the titers of 0.52 (95% CI: 0.42–  
210 0.64) (**Table 2** and **Figure 2**). The GMTs (95% CI) of the anti-RBD total antibody on Roche assay (U/mL) were  
211 6858 (5987–7856) for cases and 12559 (10672–14779) with a ratio of 0.55 (95% CI: 0.44–0.68). The predicted  
212 neutralizing antibody GMTs (95% CI) against Wild-type (NT<sub>50</sub>) were 287 (194–423) for cases and 497 (332–744)



for controls, with a ratio of 0.58 (95% CI: 0.37–0.91). The detection rate of neutralization (i.e.,  $\geq 40$  NT<sub>50</sub>) against Omicron XBB.1.16 was lower in cases than in controls (20% vs. 36%), and the GMTs (95% CI) of Omicron XBB.1.16 were 53 (44–64) for cases and 87 (61–124) for controls. The rate of neutralization detection against Omicron EG.5.1 was lower in cases than in controls (6% vs. 22%), and the GMTs (95% CI) of Omicron EG.5.1 were 41 (40–43) for cases and 57 (45–73) for controls.

The sensitivity analyses restricting to infection-naïve matched pairs yield that the difference in preinfection anti-RBD and neutralizing antibody titers between cases and controls were attenuated and no longer statistically significant. No infection-naïve cases detected neutralization against Omicron XBB.1.16 and EG.5.1.

#### *Neutralizing antibody titers across statuses of Omicron bivalent vaccination and previous infection*

There were no substantial differences in preinfection-neutralizing antibody titers against Wild-type, Omicron XBB.1.16, and Omicron EG.5.1 between individuals irrespective of their history of Omicron bivalent vaccination. Neutralization against Omicron XBB.1.16 and EG.5.1 was not detected (i.e.,  $< 40$  NT<sub>50</sub>) in all serums from infection-naïve individuals who never received the Omicron bivalent vaccine. Among infection-naïve individuals with a history of Omicron bivalent vaccine, only 21% and 4% had detectable neutralizing titers against XBB.1.16 and EG.5.1, respectively.

Previously infected individuals had higher preinfection-neutralizing antibody titers against Wild-type, Omicron XBB.1.16, and Omicron EG.5.1 than infection-naïve individuals (**Figure 3**). Irrespective of the previous infection phases, Wild-type neutralizing titers were higher in those with previous infection than those with infection-naïve (**Figure 4**). Those infected during Omicron XBB periods had the highest neutralizing antibody titers against Omicron XBB.1.16 and EG.5.1 compared to those infected in Omicron BA or earlier periods. Those infected in the Omicron BA period had statistically higher neutralizing titers against Omicron XBB.1.16 than those with infection-naïve, whereas not in titers against Omicron EG.5.1.

## **Discussion**

From June to September 2023, when Omicron XBB.1.16 and EG.5.1 were predominantly circulating in Japan, previous infection during the Omicron BA and XBB waves was associated with a 70% and 100% lower risk of subsequent symptomatic SARS-CoV-2 infection, respectively, while the Omicron BA bivalent vaccination was not associated with the risk of infection in a cohort of healthcare workers with three or more doses of vaccination. The



243 preinfection neutralizing antibody titers against Omicron XBB.1.16 and EG.5.1 were lower in infected cases than  
244 in the matched controls.

245 Although the evidence regarding the protection of previous infections and the bivalent vaccine against  
246 Omicron XBB.1.16 and EG.5.1 infection is scarce, our findings were similar to a study of U.S. healthcare workers  
247 [12]. That study reported that previous Omicron infection was associated with a 60% lower risk of subsequent  
248 infection during the dominant waves of Omicron BA.4/5, BQ, or XBB subvariants, whereas the Omicron BA bivalent  
249 vaccination was not associated with the risk of infection during the dominant wave of XBB subvariant. Regarding  
250 the protection of previous infection, our study has some strengths over the previous study. We classified previous  
251 Omicron infection by the subvariant-specific dominant phases (BA or XBB). In addition, we followed subsequent  
252 infections restricted to the dominant phase of the XBB.1.16 and EG.5.1. These gaps allowed us to estimate the  
253 Omicron BA- and XBB-specific protection against subsequent infections during the XBB.1.16 and EG.5.1 specific-  
254 waves, and we found the previous infection during Omicron XBB wave has superior protection against infection  
255 during XBB.1.16 and EG.5.1 dominant phase to those during Omicron BA wave (100% vs 70% protection).

256 In spite of much lower preinfection neutralizing titers against XBB.1.16 and EG.5.1 than those against wild-  
257 type, we found that higher neutralizing antibody titers against Omicron XBB.1.16 and EG.5.1 were associated with  
258 a lower risk of COVID-19 infection when these variants were dominant. Our findings suggest that variant-specific  
259 neutralizing antibody titers could correlate with protection against infection with its variant, even within the low  
260 titers range. We also found that the prevalence of those with hybrid immunity (vaccination and previous infection)  
261 was lower in cases than in controls (25% vs. 60%), and individuals with hybrid immunity had higher neutralizing  
262 titers against XBB.1.16 and EG.5.1 than infection-naïve individuals. Similarly, previous studies reported that  
263 neutralizing titers against XBB.1.16 and EG.5.1 were higher in vaccinated individuals with a history of infections  
264 than those without [8, 9, 19]. These results confirm that the evidence that hybrid immunity confers better protective  
265 humoral immunity than vaccination alone, which has been recognized for the risk of infection with Omicron BA or  
266 earlier variants [20, 21], can be extended to the risk of XBB.1.16 and EG.5.1 infection.

267 This study had several strengths. We rigorously matched cases and controls using a propensity score  
268 estimated by several factors potentially associated with SARS-CoV-2 infection risk, including occupational SARS-  
269 CoV-2 exposure risk, living arrangements, comorbidities, infection prevention practices, and high infection risk-  
270 behaviors. Blood samples for antibody testing were obtained before infection (1 month before the Omicron  
271 XBB.1.16 and EG.5.1 epidemic onset). Previous SARS-CoV-2 infection was determined according to the history of  
272 COVID-19 infection and results of anti-N assays, allowing us to identify undiagnosed infections. We measured the

273 neutralizing antibody titers using live viruses. However, limitations also should be acknowledged. We did not  
274 conduct active surveillance to detect SARS-CoV-2 infection during the follow-up period. Data on virus strain was  
275 not available for the present cases; however, the cases were most likely due to the Omicron XBB variant, which  
276 accounted for more than 90% of sequenced COVID-19 samples in Japan during the follow-up (June to September  
277 2023) (**Figure 1**).

## 278 **Conclusion**

279 In the era when Omicron XBB.1.16 and EG.5.1 variants were predominant and the Omicron XBB vaccine  
280 was still unavailable in Japan, previous Omicron BA or XBB infection, but not Omicron bivalent vaccination, was  
281 associated with a lower risk of SARS-CoV-2 symptomatic infection. The preinfection- and live-virus-neutralizing  
282 antibody titers against Omicron XBB.1.16 and EG.5.1 were lower in infected cases than in their matched controls.  
283 Those with a history of Omicron BA bivalent vaccine had barely detectable neutralizing titers against these variants.  
284 Our results highlight the importance of infection prevention practices when the circulating variants had high  
285 immune evasion from immunity acquired by existing vaccines.

## 288 **Acknowledgments**

### 289 *Author Contributions*

290 Drs. Yamamoto and Mizoue had full access to all data in the study and took responsibility for the integrity of the  
291 data and the accuracy of the data analysis.

292 Concept and design: Y.S., Matsuda K., Maeda K., M.T., S.H., S.W., O.N.

293 Acquisition, analysis, or interpretation of data: Y.S., Matsuda K., Maeda K., H.K., O.K., T.T., O.Y., I.N., N.T., T.S.J.,  
294 K.M., M.T.

295 Drafting of the manuscript: Y.S., M.T.

296 Critical revision of the manuscript for important intellectual content: Y.S., Matsuda K., Maeda K., T.S.J., M.T., S.H.,  
297 A.N., S.W., O.N.

298 Statistical analysis: Y.S., K.M.

299 Administrative, technical, or material support: Y.S., Matsuda K, Maeda K, H.K., O.K., T.T., O.Y., I.N., N.T., T.S.J.,  
300 K.M., M.T., S.H., A.N., S.W., O.N.

301 Supervision: M.T., O.N.

303 *Conflict of Interest Disclosures*

304 All authors: No conflicts of interest were reported.

305

306 *Funding/Support*

307 This work was supported by the NCGM COVID-19 Gift Fund (grant number 19K059 to T.M.), Japan Health  
308 Research Promotion Bureau Research Fund (grant number 2020-B-09 and 2024-B-01 to T.M.), and National  
309 Center for Global Health and Medicine (grant number 21A2013D and 23A2020D to T.M., and grant number  
310 24A1011 to S.Y.). Abbott Japan and Roche Diagnostics provided reagents for the anti-SARS-CoV-2 antibody  
311 assays.

312

313 *Role of the Funder/Sponsor*

314 The above entities had no role in the design or conduct of the study, collection, management, analysis, and  
315 interpretation of the data, preparation, review, or approval of the manuscript, or the decision to submit the  
316 manuscript for publication.

317

318 *Additional Contributions*

319 We thank Mika Shichishima for her contribution to data collection and the staff of the Laboratory Testing  
320 Department for their contribution to antibody testing.

321

322

## References

323

- 324 1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl*  
325 *J Med* **2020**; 383:2603-15.
- 326 2. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl*  
327 *J Med* **2021**; 384:403-16.
- 328 3. Cheng M-Q, Li R, Weng Z-Y, Song G. Relative effectiveness of bivalent COVID-19 vaccine: a systematic review  
329 and meta-analysis. *Frontiers in Medicine* **2024**; 10.
- 330 4. Tamura T, Ito J, Uriu K, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from  
331 recombination of two Omicron subvariants. *Nature Communications* **2023**; 14.
- 332 5. Yamasoba D, Uriu K, Plianchaisuk A, et al. Virological characteristics of the SARS-CoV-2 omicron XBB.1.16  
333 variant. *The Lancet Infectious Diseases* **2023**; 23:655-6.
- 334 6. Kaku Y, Kosugi Y, Uriu K, et al. Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against  
335 omicron subvariants including EG.5. *The Lancet Infectious Diseases* **2023**; 23:e395-e6.
- 336 7. Yang J, Hong W, Lei H, et al. Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5  
337 infection. *Signal Transduction and Targeted Therapy* **2023**; 8.
- 338 8. Wang Q, Guo Y, Zhang RM, et al. Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and  
339 XBC.1.6. *The Lancet Infectious Diseases* **2023**; 23:e397-e8.
- 340 9. Zhang L, Kempf A, Nehlmeier I, et al. Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3.  
341 *The Lancet Infectious Diseases* **2023**; 23:e391-e2.
- 342 10. Tan CY, Chiew CJ, Pang D, et al. Protective immunity of SARS-CoV-2 infection and vaccines against medically  
343 attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. *The*  
344 *Lancet Infectious Diseases* **2023**.
- 345 11. Wei J, Stoesser N, Matthews PC, et al. Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves  
346 in the UK general population. *Nature Communications* **2024**; 15.
- 347 12. Shrestha NK, Burke PC, Nowacki AS, Simon JF, Hagen A, Gordon SM. Effectiveness of the Coronavirus  
348 Disease 2019 Bivalent Vaccine. *Open Forum Infectious Diseases* **2023**; 10.
- 349 13. Yamamoto S, Oshiro Y, Inamura N, et al. Durability and determinants of anti-SARS-CoV-2 spike antibodies  
350 following the second and third doses of mRNA COVID-19 vaccine. *Clin Microbiol Infect* **2023**.
- 351 14. Yamamoto S, Maeda K, Matsuda K, et al. Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and  
352 Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-  
353 Control Matching Study. *Clin Infect Dis* **2021**.
- 354 15. Yamamoto S, Matsuda K, Maeda K, et al. Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough  
355 Infection, and Long COVID: A Propensity Score-Matched Analysis. *The Journal of Infectious Diseases* **2023**.
- 356 16. Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous treatment of human bronchial  
357 epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome  
358 coronavirus entry. *J Virol* **2012**; 86:6537-45.
- 359 17. Tsuchiya K, Maeda K, Matsuda K, et al. Neutralization activity of IgG antibody in COVID-19 convalescent  
360 plasma against SARS-CoV-2 variants. *Sci Rep* **2023**; 13.
- 361 18. Mizoue T, Yamamoto S, Konishi M, et al. Cumulative and undiagnosed SARS-CoV-2 infection among the staff  
362 of a medical research center in Tokyo after the emergence of variants. *Epidemiol Infect* **2023**:1-14.

- 363 19. Hu Y, Zou J, Kurhade C, et al. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and  
364 CH.1.1. *Emerging Microbes & Infections* **2023**.
- 365 20. Suryawanshi R, Ott M. SARS-CoV-2 hybrid immunity: silver bullet or silver lining? *Nature Reviews Immunology*  
366 **2022**; 22:591-2.
- 367 21. Faraone JN, Liu S-L. Immune imprinting as a barrier to effective COVID-19 vaccines. *Cell Reports Medicine*  
368 **2023**; 4:101291.
- 369 22. Wang Q, Guo Y, Tam AR, et al. Deep immunological imprinting due to the ancestral spike in the current bivalent  
370 COVID-19 vaccine. *Cell Reports Medicine* **2023**; 4:101258.
- 371 23. Maeda K, Higashi-Kuwata N, Kinoshita N, et al. Neutralization of SARS-CoV-2 with IgG from COVID-19-  
372 convalescent plasma. *Sci Rep* **2021**; 11.
- 373

**Table 1.** Baseline characteristics before and after propensity score matching

Characteristics	Before Matching (N=2,363)			After Matching (N=412)		
	Cases N=206	Controls N=2,157	Standardized difference	Cases N=206	Controls N=206	Standardized difference
Age, y	36.5±11.8	39.3±12.8	0.23	36.5±11.8	36.8±12.4	0.03
Female	77.7	70.4	0.17	77.7	80.1	0.06
Job						
Doctor	11.7	17.2	0.16	11.7	9.7	0.06
Nurse	44.2	36.4	0.16	44.2	46.1	0.04
Allied healthcare worker	21.4	14.7	0.17	21.4	21.4	0.00
Researcher	6.3	11.9	0.20	6.3	8.3	0.07
Administrative Staff	13.1	14.2	0.03	13.1	12.6	0.01
Others	3.4	5.6	0.11	3.4	1.9	0.09
Occupational SARS-CoV-2 exposure risk <sup>a</sup>						
Low	59.7	60.4	0.01	59.7	62.1	0.05
Moderate	20.4	21.1	0.02	20.4	21.8	0.04
High	19.9	18.5	0.04	19.9	16	0.10
Body mass index, kg/m <sup>2</sup>	21.6±3.3	21.8±3.3	0.07	21.6±3.3	21.6±3.4	0.01
Comorbid diseases <sup>b</sup>	8.7	8.2	0.02	8.7	7.3	0.05
Immunosuppression <sup>c</sup>	1.9	1	0.08	1.9	2.4	0.03
Tobacco products users <sup>d</sup>	6.8	7.3	0.02	6.8	6.3	0.02
Frequency of Alcohol drinking						
None	30.6	32.5	0.04	30.6	30.1	0.01
Occasional	32	27.1	0.11	32	33	0.02
Weekly/Daily	37.4	40.5	0.06	37.4	36.9	0.01
No. of households	2±1	2±1	0.04	2±1	2±1	0.01
No. of school-aged children <sup>e</sup>						
0	72.8	70.9	0.04	72.8	74.8	0.04
1	13.1	12.7	0.01	13.1	11.7	0.04
≥2	14.1	16.4	0.06	14.1	13.6	0.01
Infection prevention practice score <sup>f</sup>	7±2	7±2	0.04	7±2	7±2	0.03
Spending ≥30min in the 3Cs without mask						
None	59.2	61.8	0.05	59.2	57.8	0.03
1-5 times	32.5	29.1	0.07	32.5	34.5	0.04
≥6 times	8.3	9	0.03	8.3	7.8	0.02
Having dinner in a group of ≥5 people for >1h						
None	60.7	57.7	0.06	60.7	63.1	0.05
1-5 times	36.4	37.8	0.03	36.4	35.4	0.02
≥6 times	2.9	4.5	0.08	2.9	1.5	0.10

Data are presented as mean ± standard deviation for continuous variables and as numbers (percentages) for categorical variables. An absolute

standardized difference of less than 0.10 indicates a relatively small imbalance.

- a Occupational SARS-CoV-2 exposure risk was categorized as low (those not engaged in COVID-19–related work), moderate (those engaged in COVID-19–related work without heavy exposure to SARS-CoV-2), or high (those heavily exposed to SARS-CoV-2).
- b Comorbid diseases were defined as cancer, cardiovascular disease, diabetes, hypertension, chronic kidney disease, or lung disease.
- c Immunosuppression was defined as having an immunosuppressive disease or using steroids [except topical or inhaled], immunosuppressants or anticancer drugs
- d Tobacco products include conventional cigarettes and heated tobacco products.
- e School-age children include those in nurseries, kindergartens, elementary to high school, university, and with disabilities
- f Infection prevention practice score was calculated on the basis of the total score of adherences to avoiding the 3Cs, hand washing, wearing a mask, social distancing, and not touching the face, nose, or mouth, assigning 2 points to “always,” 1 point to “often,” and 0 points to others (“seldom” and “not at all”).

*Abbreviations:* 3Cs, crowded places, close-contact settings, and confined and enclosed spaces; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.



**Table 2.** Association of vaccination status, previous infection status, and preinfection antibody titers with the risk of COVID-19 infection

Variables	Cases (n=206)	Controls (n=206)	Effect size (95% CI)
<b>Vaccination status at baseline</b>			
No. of mRNA vaccine doses, %			
3	25.7	23.8	reference
4	44.7	41.3	1.01 (0.62 to 1.63) <sup>a</sup>
5	26.2	32.0	0.78 (0.47 to 1.30) <sup>a</sup>
6	3.4	2.9	1.04 (0.32 to 3.39) <sup>a</sup>
No. of Omicron bivalent vaccine doses, %			
0 (monovalent vaccine only)	55.3	50.5	reference
1	42.2	48.1	0.79 (0.52 to 1.20) <sup>a</sup>
2	2.4	1.5	1.40 (0.32 to 6.06) <sup>a</sup>
<i>Interval from last vaccination to blood sampling, mean d (95% CI)</i>	<i>287 (268–305)</i>	<i>274 [255–293]</i>	<i>12.7 (-12.9 to 38.2)<sup>b</sup></i>
<b>Previous infection status at baseline</b>			
Previous SARS-CoV-2 infection status, %			
Infection-naïve	74.3	39.8	reference
Undiagnosed infection	7.8	16.0	0.27 (0.13 to 0.55) <sup>a</sup>
Last diagnosed infection before Omicron waves	1.0	1.9	0.20 (0.03 to 1.21) <sup>a</sup>
Last diagnosed infection during Omicron BA waves	17.0	35.9	0.30 (0.18 to 0.50) <sup>a</sup>
Last diagnosed infection during Omicron XBB waves	0	6.3	0.00 (NA) <sup>a</sup>
<i>Interval from last diagnosed infection to blood sampling, mean d (95% CI)<sup>d</sup></i>	<i>367 (317–417)</i>	<i>286 (254–318)</i>	<i>81.0 (25.3 to 136.6)<sup>b</sup></i>
<b>Antibody titer at baseline</b>			
Anti-RBD IgG antibody (Abbott, AU/mL, GMT (95% CI)	6189 (5365–7141)	11959 (10238–13970)	0.52 (0.42 to 0.64) <sup>c</sup>
Anti-RBD total antibody (Roche, U/mL), GMT (95% CI)	6858 (5987–7856)	12559 (10672–14779)	0.55 (0.44 to 0.68) <sup>c</sup>
Neutralizing antibody (Wild-type, NT <sub>50</sub> ), GMT (95% CI) <sup>e</sup>	287 (194–423)	497 (332–744)	0.58 (0.37 to 0.91) <sup>c</sup>
Neutralizing antibody (Omicron BBX.1.16, NT <sub>50</sub> ), GMT (95% CI) <sup>e</sup>	53 (44–64)	87 (61–124)	0.61 (0.40 to 0.92) <sup>c</sup>
Neutralizing antibody (Omicron EG.5, NT <sub>50</sub> ), GMT (95% CI) <sup>e</sup>	41 (40–43)	57 (45–73)	0.72 (0.56 to 0.92) <sup>c</sup>
<b>Antibody titer at baseline restricted to infection-naïve pairs</b>			
Anti-RBD IgG antibody (Abbott, AU/mL, GMT (95% CI) <sup>f</sup>	4960 (3640–6280)	5433 (3760–7107)	0.91 (0.59 to 1.40) <sup>c</sup>
Anti-RBD total antibody (Roche, U/mL), GMT (95% CI) <sup>f</sup>	5611 (4076–7145)	5775 (3458–8091)	0.97 (0.57 to 1.65) <sup>c</sup>
Neutralizing antibody (Wild-type, NT <sub>50</sub> ), GMT (95% CI) <sup>f</sup>	129 (67–191)	177 (49–305)	0.73 (0.32 to 1.67) <sup>c</sup>
Neutralizing antibody (Omicron BBX.1.16), n (%) of >40 NT <sub>50</sub> <sup>g</sup>	0/12 (0)	2/12 (16.7)	–
Neutralizing antibody (Omicron EG.5), n (%) of >40 NT <sub>50</sub> <sup>g</sup>	0/12 (0)	0/12 (0)	–

<sup>a</sup> The odds ratio of COVID-19 infection across exposure groups, estimated using the conditional logistic regression model.

<sup>b</sup> The mean difference between cases and controls, estimated using the generalized estimating equation model.

<sup>c</sup> The GMT ratio for cases to controls, estimated using the generalized estimating equation model.

<sup>d</sup> analyzed among those with a history of COVID-19 diagnosis (no. of case/control: 37/91).

<sup>e</sup> analyzed among 50 matched pairs randomly selected from 206 matched pairs.

<sup>f</sup> analyzed among 57 infection-naïve pairs.

<sup>g</sup> analyzed among 12 infection-naïve pairs.

*Abbreviations:* AU, arbitrary units; CI, confidence interval; GMT, geometric mean titer; NT<sub>50</sub>, 50% neutralization titer; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; NA, not applicable.

## Figure Legends

**Figure 1.** Relative frequency of circulating SARS-CoV-2 variants from June to September 2023 in Japan.

The distribution of SARS-CoV-2 lineages in Japan during the study period (June – September 2023) was analyzed using all domestic genome sequences registered in the GISAID EpiCov database (<https://gisaid.org>). For lineage analysis, the extracted sequences (n=27,899) were applied to the Phylogenetic Assignment of Named Global Outbreak Lineages (PANGOLIN) version 4.3.1 with pangolin-data 1.25.1.

**Figure 2.** Comparison of the preinfection live-virus neutralizing and anti-RBD antibody titers between propensity-score matched cases and controls.

Preinfection anti-RBD IgG antibody titers were measured using the Abbott reagent (**A**), and anti-RBD total antibody titers were measured with Roche reagent (**B**) among 206 cases with breakthrough infection and 206 matched controls. In addition, the live-virus neutralizing antibody titers against Wild-type (**C**), Omicron XBB.1.16 (**D**), and Omicron EG.5.1 (**E**) among the 50 matched pairs were randomly selected from 206 matched pairs. In each panel, the horizontal bars indicate the geometric mean titers, and the I-shaped bars indicate the geometric standard deviations. The limit of detection (LOD) of the neutralizing assay is 40, as shown by dashed horizontal lines. The number (%) of the upper LOD is denoted above the X-axis.

Abbreviations: AU, arbitrary units; IgG, immunoglobulin G; NT<sub>50</sub>, 50% neutralizing titer; RBD, receptor-binding domain

**Figure 3.** Comparison of the preinfection live-virus neutralizing antibody titers across the histories of Omicron bivalent vaccine and prior SARS-CoV-2 infection.


Shown are the live-virus neutralizing antibody titers against Wild-type (**A**), Omicron XBB.1.16 (**B**), and Omicron EG.5.1 (**C**) among the 100 samples from 50 matched pairs. In each panel, the horizontal bars indicate the geometric mean titers, and the I-shaped bars indicate the geometric standard deviations. The limit of detection (LOD) of the neutralizing assay is 40, as shown by dashed horizontal lines. The number (%) of the upper LOD is denoted above the X-axis.






Abbreviations: NT<sub>50</sub>, 50% neutralizing titer; RBD, receptor-binding domain




**Figure 4.** Neutralizing antibody titers across the timing of previous infection.

Shown are the geometric mean titers of preinfection-neutralizing antibodies against Wild-type (**A**), Omicron XBB.1.16 (**B**), and EG.5.1 (**C**) across the timing of the previous infection, estimated using a linear regression model while adjusting age, sex, a history of Omicron bivalent vaccination, and the interval between last vaccination and blood sampling. The sample size of infection-naïve, Pre-Omicron, Omicron BA, and Omicron XBB groups are 58, 2, 22, and 2, respectively. Individuals with undiagnosed infection and having neutralizing titers (n=18) were not included in this analysis since their infection timing was unclear. We defined each previous infection phase as follows: Pre-Omicron (February 2020 to December 2021), Omicron BA (January 2022 to March 2023), and Omicron XBB (April 2024 to June 2024). Bars indicate estimated geometric mean titers, and I-shaped bars indicate 95 confidence intervals.

### Japan, Jun. to Sep. 2023, n=27,899




**A****B****C****D****E**




**A****Wild-type**

0.01

**B****Omicron XBB.1.16**

&lt;math&gt;&lt;0.001&lt;/math&gt;

**C****Omicron EG.5.1**

&lt;math&gt;&lt;0.001&lt;/math&gt;

